S. Denmeade

529 total citations
13 papers, 112 citations indexed

About

S. Denmeade is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, S. Denmeade has authored 13 papers receiving a total of 112 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 5 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Molecular Biology. Recurrent topics in S. Denmeade's work include Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Prostate Cancer Diagnosis and Treatment (3 papers). S. Denmeade is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Prostate Cancer Diagnosis and Treatment (3 papers). S. Denmeade collaborates with scholars based in United States, Brazil and United Kingdom. S. Denmeade's co-authors include Michael A. Carducci, Jianqing Lin, John T. Isaacs, Saeed R. Khan, Glenn J. Bubley, Mary Ellen Taplin, Chris Haqq, Michael P. Smith, Howard I. Scher and Johann S. de Bono and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and European Journal of Cancer.

In The Last Decade

S. Denmeade

12 papers receiving 107 citations

Peers

S. Denmeade

PRM

ONCOL

RNMI

Amruta Shrikhande Denmark

Colleen Niland Australia

Rhiannon Coulson Australia

Jennifer H. Choe United States

Rajni Sonavane United States

J.J. Soto Castillo Spain

Anjali V. Sheahan United States

Vanina Toffessi Tcheuyap United States

Sarina Cameron Australia

Jon Welti United Kingdom

Amruta Shrikhande Denmark

S. Denmeade

52 ×1.0

PRM

119 ×2.4

41 ×1.0

33 ×1.1

ONCOL

24 ×1.6

RNMI

Citations per year, relative to S. Denmeade S. Denmeade (= 1×) peers Amruta Shrikhande

Countries citing papers authored by S. Denmeade

Since Specialization

Citations

This map shows the geographic impact of S. Denmeade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Denmeade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Denmeade more than expected).

Fields of papers citing papers by S. Denmeade

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Denmeade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Denmeade. The network helps show where S. Denmeade may publish in the future.

Co-authorship network of co-authors of S. Denmeade

This figure shows the co-authorship network connecting the top 25 collaborators of S. Denmeade. A scholar is included among the top collaborators of S. Denmeade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Denmeade. S. Denmeade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Tran, Elizabeth, Alexander H. Song, Elizabeth Pan, et al.. (2024). Bipolar androgen therapy for treatment of metastatic castration‐resistant prostate cancer: A case series. The Prostate. 85(1). 40–47.

Chen, Jiayu, Qizhi Zheng, Jessica Hicks, et al.. (2023). MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression. JCI Insight. 8(24). 6 indexed citations

Deek, Matthew P., Kekoa Taparra, Ryan Phillips, et al.. (2020). Metastasis Directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-Resistant Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 108(3). e893–e894. 5 indexed citations

Meyer, Alexa, Steven P. Rowe, Michael A. Carducci, et al.. (2019). Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. European Urology Supplements. 18(1). e1930–e1930. 8 indexed citations

Tran, Phuoc T., Noura Radwan, Ryan Phillips, et al.. (2018). OC-0505: Interim results of a randomized trial of observation versus SABR for oligometastatic prostate cancer. Radiotherapy and Oncology. 127. S261–S261. 6 indexed citations

Phillips, Ryan, Noura Radwan, Ashley E. Ross, et al.. (2018). Interim Results of a Randomized Trial of Observation Versus SABR for Castration-Sensitive Oligometastatic Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 102(3). e134–e135. 1 indexed citations

Mahalingam, Devalingam, S. Denmeade, David O. Cosgrove, et al.. (2012). 601 A First-in-human, Phase 1 Clinical Study of the Safety, Tolerability and Pharmacokinetics (PK) of G-202, a Thapsigargin-based PSMA-activated Prodrug, in Patients with Advanced Solid Tumors. European Journal of Cancer. 48. 184–185. 1 indexed citations

Denmeade, S., et al.. (2011). 7047 POSTER A Phase I Pharmacodynamic Dose Escalation Study of Steroid Sulphatase Inhibitor Irosustat in Patients With Prostate Cancer. European Journal of Cancer. 47. S499–S499. 5 indexed citations

Lin, Jianqing, S. Denmeade, & Michael A. Carducci. (2009). HIF-1α and Calcium Signaling as Targets for Treatment of Prostate Cancer by Cardiac Glycosides. Current Cancer Drug Targets. 9(7). 881–887. 35 indexed citations

10.

Danila, Daniel C., Johann S. de Bono, Charles J. Ryan, et al.. (2009). Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto). Journal of Clinical Oncology. 27(15_suppl). 5048–5048. 15 indexed citations

11.

Carducci, Michael A., Jeffrey S. Weber, S. Denmeade, et al.. (2007). Phase I trial of docetaxel (D) plus samarium¹⁵³ (Sm ¹⁵³) in patients (pts) with hormone refractory prostate cancer (HRPC). Journal of Clinical Oncology. 25(18_suppl). 15547–15547. 1 indexed citations

12.

Bajaj, Gaurav, Elizabeth Garrett‐Mayer, Роберто Пили, et al.. (2005). A phase II study of imatinib mesylate in prostate cancer patients with evidence of biochemical relapse following definitive radical retropubic prostatectomy or radiation therapy. Journal of Clinical Oncology. 23(16_suppl). 3092–3092. 1 indexed citations

13.

Denmeade, S., et al.. (2002). A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. Bioorganic & Medicinal Chemistry Letters. 12(17). 2459–2461. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact